Engineering Deep & Durable B Cell Depletion in Autoimmune Disease: Translating T-Cell Engager Candidates Beyond Oncology
Time: 2:00 pm
day: Day One
Details:
- Introducing cizutamig and CND261, a BCMAxCD3 and CD20xCD3 bispecific T-Cell engager, respectively. Both were originally developed in oncology and are now advancing into autoimmune disease
- Discussing what is known and unknown on targeting different B cell antigens (e.g. BCMA, CD19, CD20) to maximize clinical benefit in autoimmune diseases
- Sharing views on different product profiles with TCEs beyond just immune reset
